CL2016000999A1 - Anticuerpos anti-cd38 específicos para tratar cánceres humanos - Google Patents

Anticuerpos anti-cd38 específicos para tratar cánceres humanos

Info

Publication number
CL2016000999A1
CL2016000999A1 CL2016000999A CL2016000999A CL2016000999A1 CL 2016000999 A1 CL2016000999 A1 CL 2016000999A1 CL 2016000999 A CL2016000999 A CL 2016000999A CL 2016000999 A CL2016000999 A CL 2016000999A CL 2016000999 A1 CL2016000999 A1 CL 2016000999A1
Authority
CL
Chile
Prior art keywords
antibodies
specific anti
human cancers
treat human
antibody
Prior art date
Application number
CL2016000999A
Other languages
English (en)
Inventor
Blake Tomkinson
Antoine Deslandes
Krzystof J Grzegorzewski
Marie-Laure Ozoux
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2016000999A1 publication Critical patent/CL2016000999A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MÉTODO PARA TRATAR UN SUJETO QUE TIENE MIELOMA MÚLTIPLE RECIDIVANTE Y/O REFRACTARIO QUE COMPRENDE LA ADMINISTRACIÓN DE UN ANTICUERPO ANTI-CD38; Y COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE ANTICUERPO ANTI-CD38.
CL2016000999A 2013-10-31 2016-04-27 Anticuerpos anti-cd38 específicos para tratar cánceres humanos CL2016000999A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361898309P 2013-10-31 2013-10-31
EP14306220 2014-07-31

Publications (1)

Publication Number Publication Date
CL2016000999A1 true CL2016000999A1 (es) 2016-11-25

Family

ID=57908702

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000999A CL2016000999A1 (es) 2013-10-31 2016-04-27 Anticuerpos anti-cd38 específicos para tratar cánceres humanos

Country Status (9)

Country Link
US (1) US20190284294A1 (es)
JP (2) JP6914283B2 (es)
CL (1) CL2016000999A1 (es)
ES (1) ES2825625T3 (es)
HK (1) HK1223116A1 (es)
IL (1) IL281541A (es)
PH (1) PH12016500677A1 (es)
SG (1) SG10201913447SA (es)
UA (1) UA120748C2 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US12006367B2 (en) 2014-11-04 2024-06-11 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4142791A1 (en) * 2020-04-29 2023-03-08 TeneoOne, Inc. Methods of treating multiple myeloma
WO2021259227A1 (zh) * 2020-06-23 2021-12-30 江苏康缘药业股份有限公司 抗cd38抗体及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US12006367B2 (en) 2014-11-04 2024-06-11 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production

Also Published As

Publication number Publication date
JP6914283B2 (ja) 2021-08-04
SG10201913447SA (en) 2020-02-27
ES2825625T3 (es) 2021-05-17
UA120748C2 (uk) 2020-02-10
US20190284294A1 (en) 2019-09-19
HK1223116A1 (zh) 2017-07-21
PH12016500677A1 (en) 2016-05-30
IL281541A (en) 2021-05-31
JP2019070004A (ja) 2019-05-09
JP2021105044A (ja) 2021-07-26

Similar Documents

Publication Publication Date Title
TN2015000396A1 (en) Antibody drug conjugates
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
MX2015011670A (es) Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
MX2015008313A (es) Terapia de combinacion de anticuerpos anti-her3.
MA39896A (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
MX2017002862A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso.
EA201790475A1 (ru) Способы лечения системной красной волчанки с использованием доменного антитела против cd28
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
CL2016000999A1 (es) Anticuerpos anti-cd38 específicos para tratar cánceres humanos
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
AR098221A1 (es) Conjugados de anticuerpo anti-efna4-fármaco
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.